Prohost Biotech
Prohost Biotech
Send Message
Prohost Biotech
Stop FollowingProhost Biotech
View as an RSS Feed
View Prohost Biotech's Articles BY TICKER:
- The True Value Of Seattle Genetics
- Sarepta: What's Going On?
- ImmunoGen Offers New Hope For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Cancers
- A Quick Response To Ariad's Conference Call
- Northwest Biotherapeutics: An Example Of Reform In The Drug Approval Process
- Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?
- Isis: FDA Approval Of Kynamro Promises A Bright Future For Company
- XOMA: Will The Love-Hate Marriage With Investors Finally End Up In A Stable Relationship?
- Theravance: Tempting To Investors As Well As Partners
- Ariad: Iclusig's Approval Deserves Honoring The Developer, Not Bashing Its Stock
- The Road Toward Far-Reaching Therapeutics Through Illumina, Sarepta
- ImmunoGen's Press Release Is More Than Mere News
- ChemoCentryx: A Leader Of A New Line Of Investigational Treatments
- Biotech: On The Way To Meeting Highly Ambitious Expectations
- ImmunoGen: 2 Pieces Of Good News In 1 Announcement
- Why A Sell-Off Among The Best Oncology Biotech Firms?
- Pluristem: 2 Cases Enough To Raise Investor Curiosity?
- An Assault On Vertex, Enthusiasm Building Around Xoma
- Pharmacyclics: Product Pipeline Overshadows Stock Market Influence
- ImmunoGen Has Good News To Share
- Aveo And Exelixis At The Finish Line
- Redefining The Meaning Of 'Creating Shareholder Value' In Biotech
- Vertex: Well-Equipped To Own The Future
- Illumina And Human Genome: Reasons For Rejections Of Takeovers
- Affymax Poised To Take On Amgen?
- Ariad's mTOR And The FDA Committee
- Ariad Prepares For FDA Committee
- Agenus Continues to Outperform
- Addressing Vertex / Gilead Confusion
- Pharmacyclics: When The Power Of A Pipeline Overshadows The Market's Influence On Value
- Illumina, Roche And Fairness
- Xoma's New Plans Bring Hesitant Hope
